Study of three drugs for advanced melanoma after first treatment
Part of Cancer, Skin clinical trials.
This trial tests a combination of three drugs (fruquintinib, cadonilimab, and temozolomide) for people with advanced melanoma that has already been treated with at least one prior therapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV melanoma that has spread to other parts of the body.
- You have already tried at least one standard treatment (first-line therapy) and it didn't work or you couldn't continue it. If you have a BRAF V600 mutation, you must have also tried targeted therapy.
- You are between 18 and 75 years old.
- You do not have active brain metastases (cancer in the brain that is causing symptoms).
- Your melanoma did not start in the skin (cutaneous melanoma is not allowed).
- You are generally in good health (able to do daily activities, with good organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (Fluzoparib, Camrelizumab, and Temozolomide) for people with advanced melanoma that has spread or cannot be removed by surgery. It is for those who have a specific genetic change (HR or SF3B1 mutation) and have not been treated with a PARP inhibitor before.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a combination of three medicines (pucotenlimab, lenvatinib, and temozolomide) given before surgery to shrink stage IIB or III acral melanoma. The goal is to see if this treatment can improve outcomes for people whose melanoma can be removed by surgery.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests a combination of two drugs, cadonilimab and anlotinib, for people with melanoma that has gotten worse or spread after their first treatment. It aims to see if this new combination can help when standard options have stopped working.
Hear when a new Malignant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.